Spruce Biosciences (SPRB) Interest Expenses (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Interest Expenses of $10.1 million for Q1 2026, up 28055.56% year-over-year from N/an in Q1 2025, and up 63450.0% quarter-over-quarter from -$16000.0 in Q4 2025.
Spruce Biosciences (SPRB) Interest Expenses (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Interest Expenses for 8 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 28055.56% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (up 6080.49% YoY), while the FY2025 annual figure was $3.3 million, up 847.09% from the prior year.
- Interest Expenses grew to $10.1 million in Q1 2026 per SPRB's latest filing, from -$16000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $10.1 million in Q1 2026 and bottomed at -$26000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $764882.4 across 5 years, with a median of $106000.0 in 2023.
- Annual changes were most pronounced in 2024 — Interest Expenses sank 124.53% — and 2026, when it soared 28055.56%.
- Spruce Biosciences' Interest Expenses stood at $201000.0 in 2022, then plunged by 47.26% to $106000.0 in 2023, then plunged by 124.53% to -$26000.0 in 2024, then surged by 38.46% to -$16000.0 in 2025, then jumped by 63450.0% to $10.1 million in 2026.
- Business Quant data shows SPRB's Interest Expenses at $10.1 million in Q1 2026, -$16000.0 in Q4 2025, and $19000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.51 Mn |
| Jun 30, 2026 | 9.51 Mn |
| Mar 31, 2026 | 10.14 Mn |
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 97,000.00 |
| Mar 31, 2024 | 97,000.00 |